Back to Journals » Clinical Ophthalmology » Volume 7

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Authors Liu Y, Mao W

Received 11 October 2012

Accepted for publication 20 November 2012

Published 21 December 2012 Volume 2013:7 Pages 7—14

DOI https://doi.org/10.2147/OPTH.S30951

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Yang Liu, Weiming Mao

Department of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX

Abstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

Keywords: tafluprost, prostaglandin analog, glaucoma, intraocular pressure, preservative-free formulation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]